Numair Arshad

Faculty

Numair Arshad is a dedicated student pursuing a Doctor of Pharmacy (PharmD) degree with a keen interest in pharmacology and life sciences. With a robust background in scientific writing, Numair has honed his skills during his tenure as a medical writer at Rhenix LifeSciences. During this time, he authored nearly 50 detailed white papers on various disease subjects, in addition to a comprehensive review paper. His expertise extends to delivering engaging CellTalk presentations, showcasing his proficiency in communicating complex scientific concepts effectively.

Over the past three years, Numair has immersed himself in scientific writing. At Rhenix LifeSciences, he played a pivotal role in producing high-quality scientific content, demonstrating his commitment to advancing knowledge in life sciences.

Numair's passion lies in the intersection of pharmacology and omics, where he sees immense potential for revolutionizing drug development and identifying novel therapeutic targets. He is deeply enthusiastic about leveraging omics technologies and bioinformatics to streamline the drug development process and catalyze advancements in medical research.

With a dedication to scientific writing and a profound interest in the omics field, Numair Arshad is poised to make significant contributions to the intersection of pharmacology, omics, and medical writing.

Google Scholar

Recent Publications

Link to full Article

Drug Delivery in Leptomeningeal Disease: Navigating Barriers and Beyond; Arshad, Numair, Nupur Biswas, Jaya Gill, Santosh Kesari, and Shashaanka Ashili; Drug Delivery 31 (1): 2375521 (2024).

This article explores the challenges of drug delivery in leptomeningeal disease (LMD), a severe cancer complication. Traditional treatments like intrathecal and systemic chemotherapy face issues with drug distribution and patient compliance. Emerging approaches, including nanocarrier-mediated delivery, liposomal formulations, and BCSFB modulation, show promise in improving efficacy and reducing side effects. These advancements aim to enhance patient outcomes and quality of life.

Link to full Article

MicroRNA-21 Silencing in Diabetic Nephropathy: Insights on Therapeutic Strategies; Yogita Dhas, Numair Arshad, Nupur Biswas, Lawrence Jones, and Shashaanka Ashili; Biomedicines 11 (9), 2583 (2023).

Diabetic kidney disease is a grave complication leading to kidney damage and silencing of microRNA-21 is a promising treatment avenue. It requires an understanding of miR-21's involvement in diabetic induced kidney damage. Various methods for miR 21 silencing are under preliminary exploration. Current research offers hope for enhancing the quality of life for individuals affected by diabetic induced kidney disease.

Numair Arshad

Recent Publications

Collaborators